Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial

Authors: Roy S. Herbst, Hendrik‐Tobias Arkenau, Rafael Santana-Dávila, Emiliano Calvo, Luis Paz‐Ares, Philippe A. Cassier, Johanna C. Bendell, Nicolas Penel, Matthew Krebs, Juan Martín-Liberal, Nicolás Isambert, A. Segado Soriano, Martin Wermke, Jennifer L. Cultrera, Ling Gao, Ryan C. Widau, Gu Mi, Jin Jin, David Ferry, Charles S. Fuchs, Daniel P. Petrylak, Ian Chau - The Lancet 2019 cited by 275